We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Umoja Biopharma has raised $210m in a Series B funding round to progress its pipeline of in vivo engineered CAR T cell immunotherapies for the treatment of solid tumours and hematologic malignancies into the clinic.